Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Search
Trial Profile

A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LMB 100 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Feb 2024 Status changed from active, no longer recruiting to discontinued, this study was terminated due to slow accrual.
  • 01 Sep 2022 Status changed from recruiting to active, no longer recruiting.
  • 15 May 2021 Planned End Date changed from 31 Mar 2022 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top